8-K: DENTSPLY SIRONA Reports Q1 2026 Results, Reiterates Outlook

DENTSPLY SIRONA Inc. announced its first fiscal quarter 2026 financial results, reporting net sales of $880 million and reiterating its full-year outlook.

Summary

• DENTSPLY SIRONA reported net sales of $880 million for the first fiscal quarter ended March 31, 2026, a slight increase of 0.1% compared to the same period in the prior year.
• The company reported a GAAP net loss of ($0.05) per share, compared to GAAP earnings of $0.10 per share in Q1 2025.
• Adjusted EBITDA was $129 million, with an adjusted EBITDA margin of 14.7%, a decrease from 19.0% in Q1 2025.
• Adjusted EPS was $0.27, down from $0.44 in Q1 2025.
• The company launched Smart View-Detect, an AI-enabled diagnostic aid for CBCT scans, which has received FDA clearance and CE-marking.
• New distribution agreements were established with Atlanta Dental Supply and Benco Dental.
• DENTSPLY SIRONA is implementing a new capital allocation strategy focused on debt reduction, liquidity management, and working capital improvement.
• The company reiterated its full-year 2026 outlook for net sales between $3.5 billion and $3.6 billion, and adjusted EPS between $1.40 and $1.50.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant declines in key profitability metrics like adjusted EBITDA and EPS, despite slight net sales growth and a reiterated outlook.

Positives

• Net sales increased slightly by 0.1% year-over-year to $880 million.
• Launched Smart View-Detect, an AI-enabled diagnostic aid, receiving FDA clearance and CE-marking.
• Secured new distributor agreements with Atlanta Dental Supply and Benco Dental.
• Operating cash flow improved significantly to $40 million from $7 million in the prior year's quarter.
• Initiated a new capital allocation strategy focused on debt reduction and working capital improvement.

Negatives

• Reported a GAAP net loss of ($0.05) per share, a decline from GAAP earnings of $0.10 per share in Q1 2025.
• Adjusted EBITDA decreased by 22.8% to $129 million, and the adjusted EBITDA margin fell to 14.7% from 19.0%.
• Adjusted EPS decreased by 39.0% to $0.27 from $0.44 in the prior year.
• GAAP gross margin decreased to 48.5% from 53.0% year-over-year.
• Free cash flow remained negative at ($12) million, consistent with the prior year's quarter.

Risks

• Near-term performance is impacted by external pressures and investment timing.
• The company's forward-looking statements are subject to numerous assumptions, risks, uncertainties, and other factors that could cause actual results to differ materially.
• Risks are described in Part I, Item 1A, 'Risk Factors' of the Company's most recent Annual Report on Form 10-K and subsequent filings.

Future Outlook

The Company is maintaining its 2026 outlook for net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50, expecting momentum to build throughout the year.

Management Comments

• "We are executing our Return-to-Growth Action Plan as expected, and our first quarter results reflect our current stage of transformation."
• "While near-term performance is impacted by external pressures and investment timing, we are making solid progress toward sustainable growth."
• "During the quarter, we advanced our commercial restructuring and continued portfolio innovation, with early traction from distributor partners."
• "We remain confident in our strategy, maintain our full-year outlook, and expect momentum to build throughout the year."

Industry Context

StockSavvy.ai notes that DENTSPLY SIRONA's Q1 2026 results, while showing slight net sales growth, indicate pressure on profitability metrics like adjusted EBITDA and EPS, potentially reflecting broader industry challenges in the dental technology sector related to external pressures and investment timing.

Comparison to Industry Standards

• No direct comparisons to specific industry benchmarks or competitors were provided in the filing.
• The filing focuses on the company's own historical performance and future outlook.

Stakeholder Impact

• Shareholders may be impacted by the decline in profitability metrics and the GAAP net loss.
• Employees may be affected by the ongoing commercial restructuring and transformation activities.
• Distributors and customers may benefit from new product innovations like Smart View-Detect and new distribution agreements.

Next Steps

• Continue executing the Return-to-Growth Action Plan.
• Build momentum throughout the remainder of the year.
• Implement new capital allocation strategy (debt reduction, liquidity management, working capital improvement).

Key Dates

Recommendation

While the company is reiterating its full-year outlook, the significant year-over-year decline in profitability metrics (Adjusted EBITDA, Adjusted EPS, GAAP Net Loss) suggests ongoing challenges that warrant a cautious 'hold' stance until sustained improvement is demonstrated.

Keywords

DENTSPLY SIRONA, XRAY, 8-K, Financial Results, Q1 2026, Dental Products, Medical Devices, SEC Filing